Jennifer A. Whitaker
A5102989337- SARS-CoV-2 and COVID-19 Research
- Immunotherapy and Immune Responses
- Herpesvirus Infections and Treatments
- Viral gastroenteritis research and epidemiology
- Ocular Infections and Treatments
- Immunodeficiency and Autoimmune Disorders
- Blood groups and transfusion
- Glycosylation and Glycoproteins Research
- Salmonella and Campylobacter epidemiology
- Viral Infections and Immunology Research
- Hepatitis C virus research
- Chronic Lymphocytic Leukemia Research
- Sinusitis and nasal conditions
- Poxvirus research and outbreaks
- Infectious Diseases and Tuberculosis
- RNA and protein synthesis mechanisms
- vaccines and immunoinformatics approaches
- Vibrio bacteria research studies
- Yersinia bacterium, plague, ectoparasites research
- Aquaculture disease management and microbiota
- Pharmacological Effects of Natural Compounds
- Immune Response and Inflammation
- Parvovirus B19 Infection Studies
- Influenza Virus Research Studies
- Dermatology and Skin Diseases
Baylor College of Medicine
2023-2024
Mayo Clinic in Florida
2013-2018
Emory University
2009-2017
HOPE Clinic
2012-2017
Mayo Clinic
2014
Mayo Clinic in Arizona
2012
Indiana University Bloomington
2003
Primary vaccination with mRNA-1273 (100-µg) was safe and efficacious at preventing coronavirus disease 2019 (COVID-19) in the previously reported, blinded Part A of phase 3 Coronavirus Efficacy (COVE; NCT04470427) trial adults (≥18 years) across 99 U.S. sites. The open-label (Parts B C) primary objectives were evaluation long-term safety effectiveness plus a 50-µg booster dose; immunogenicity secondary objective. Of 29,035 participants, 19,609 received boosters (mRNA-1273 [n = 9647];...
Abstract In a randomized clinical trial, we compare early neutralizing antibody responses after boosting with bivalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines based on either BA.1 or BA.4/BA.5 Omicron spike protein combined wild-type spike. Responses against SARS-CoV-2 variants exhibited the greatest reduction in titers currently circulating subvariants for both vaccines.
Background Tuberculosis is a major occupational hazard in low and middle-income countries. Limited data exist on serial testing of healthcare workers (HCWs) with interferon-γ release assays (IGRAs) for latent tuberculosis infection (LTBI), especially We sought to evaluate the rates risk factors LTBI prevalence test conversion among HCWs using tuberculin skin (TST) QuantiFERON-TB Gold In-tube assay (QFT-GIT). Methods A prospective longitudinal study was conducted country Georgia. Subjects...
Abstract The incidence and severity of herpes zoster (HZ) increases with age. live attenuated vaccine generates immune responses similar to HZ. We compared the in young older adults increase our understanding characteristics that may contribute increased susceptibility HZ adults. Young (25–40 y; n = 25) (60–80 33) had magnitude memory varicella-zoster virus (VZV) ex vivo restimulation measured by responder cell-frequency flow cytometry, but were delayed Only an dual-function VZV-specific...
We report the first successful design of a self-associating antiparallel coiled coil, APH. The simultaneous application Coulombic and hydrophobic components results in decided preference for alignment as judged by HPLC, sedimentation equilibrium, chemical denaturation data. designed peptide is comparable stability to naturally occurring leucine zipper peptides can be expressed bacteria. These properties APH suggest potential vivo protein fusion biomaterials applications.
Amikacin is a first-line treatment for Aeromonas infection due to high efficacy. There are few reports of aminoglycoside-resistant spp. We report soft tissue containing multiple pathogens, including strain hydrophila resistant amikacin, tobramycin, and cephalosporins.
Our patient, we believe, experienced a primary HSV-2 infection manifested by fever, malaise, and orogenital mucocutaneous lesions. With resolution of systemic manifestations, at time theorized rise in antibody levels, he had thrombocytopenic purpura which persisted for several weeks. An immune disorder secondary to similar that postrubella is postulated. If this theory correct, severe yet one more the many observed complications HSV infection.
For COVAIL recipients of a coronavirus disease 2019 (COVID-19) Sanofi booster vaccine, neutralizing antibody titers were assessed as correlate risk (CoR) COVID-19. Peak and exposure-proximal inverse CoRs with covariate-adjusted hazard ratios (95% confidence intervals) 0.30 (0.11, 0.78) 0.25 (0.07, 0.85) per 10-fold increase in weighted average titer.
We compared the serologic responses of 1 dose versus 2 doses a variant vaccine (Moderna mRNA-1273 Beta/Omicron BA.1 bivalent vaccine) in adults. A 2-dose boosting regimen with did not increase magnitude or durability serological to single boost.